Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Sticks To Hard Line On Abuse-Deterrent Opioids; Acura Takes A Hit

This article was originally published in The Pink Sheet Daily

Executive Summary

Acura Pharmaceuticals’ stock fell 11% May 28 after the company revealed that FDA advised an abuse liability study for its hydrocodone/acetaminophen product would not support an abuse liability claim.

You may also be interested in...

Egalet Ramps Up Commercial Ahead Of Abuse-Deterrent Pain Drug Filing

The specialty pharma has relaunched two drugs for pain – Sprix and Oxaydo – supported by a 50-person sales team, laying the groundwork to eventually bring to market an abuse-deterrent, extended-release morphine product.

Abuse-Deterrent Opioid Claims Need Studies, Studies And More Studies

FDA’s review of Purdue’s Targiniq ER, one of only two opioids with approved abuse-deterrent claims, shows that the agency’s skepticism about the state of the technology to deter opioid abuse can be overcome – by an exhaustive set of comparisons in clinical, in vitro and PK studies.

In Brief: Amarin Perseveres With Vascepa Outcomes Trial, Cochrane Review Reignites Lucentis Cost Debate

Plus Acura’s own appeal on abuse-deterrent opioid, TG Therapeutics gets FDA buy-in for ublituximab accelerated approval plan, and Amgen presents more analysis supporting heart failure drug ivabradine after Servier’s failed outcomes trial.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts